Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
2024 Election
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Baseball legend Mays dies
Arrested for DWI
Deficit to reach $1.9T in '24
Vegas monolith found
Gag order appeal dismissed
Alleged misconduct probe
Putin in North Korea
Plead not guilty
11.3M watched final episode
Meta faces scam ads suit
Bezos addresses turmoil
Price label violation fine
Boeing CEO apologizes
LAUSD OKs cellphone ban
TX pastor Morris resigns
Sues for defamation
World's most valuable firm
Paul to fight Mike Perry
First tropical storm warning
TH to legalize gay marriage
Club Q shooter pleads guilty
Golden Globe winner dies
2 killed in CO plane crash
Starliner return delayed
Premiere hits 7.8M viewers
Plans immersive experiences
Luxury sales flattening
VA GOP primary win
FDA threatens legal action
CA State Fair to allow weed
Cause of death revealed
Mass. 911 outage resolved
Clean energy job boost rules
Bump stock ban blocked
Embezzlement probe
CA wildfires spread rapidly
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
FDA Expands Use of RSV Vaccine to Include More Adults
The FDA expanded the approval of GSK's respiratory syncytial virus (RSV) vaccine (Arexvy) to include adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease (LRTD) due to underlying conditions, the company announced on Friday.
FDA approves RSV vaccine for adults 50 to 59
The Arexvy respiratory syncytial virus (RSV) vaccine, which is already approved for adults 60 and up, is now indicated for use in people ages 50 to 59 years old thanks to recent Food and Drug Administration approval.
FDA approves first RSV vaccine for use in at-risk adults over 50
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker,
FDA approves Moderna's RSV vaccine, its second marketed product
The Food and Drug Administration approved Moderna's RSV vaccine to prevent lower respiratory tract disease in adults aged 60 or older
FDA Gives Nod to RSV Vaccine for People in Their 50s
For the first time, an RSV vaccine has been approved for use in adults in their fifties. GSK's Arexy appears to have similar safety for folks ages 50-59 as that see
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Moderna's RSV vaccine, the first RSV vaccine to use mRNA, earned FDA approval for adults 60 and up. Here's what you need to know.
FDA Approves New RSV Vaccine for Individuals Aged 50-59
On Friday, the Food and Drug Administration (FDA) approved Arexvy, a vaccine designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), for
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
GSK GSK announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is currently approved in the United States,
Drug Store News
2d
Moderna receives FDA nod for RSV vaccine mRESVIA
Moderna has received the Food and
Drug
Administration’s approval for RESVIA (mRNA-1345), an mRNA
respiratory syncytial ...
The American Journal of Managed Care
8d
FDA Approves Expanded Age Indication for RSV Vaccine Arexvy
The first
respiratory syncytial virus
(
RSV
)
vaccine
has been approved for adults aged 50 to 59 years who are at ...
Des Moines Register
18d
FDA approves Moderna's RSV vaccine, its second marketed product
The U.S. Food and
Drug
Administration has approved Moderna's
respiratory syncytial virus
vaccine
, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...
1d
An RSV Vaccine From Moderna Passes Phase III Trial Amid Viral Surge
Late Tuesday, Moderna announced the seemingly successful Phase III trial results of its experimental RSV vaccine. In older ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback